risankizumab,apremilast
abbvie,amgen
['fortify', 'crohn', 'advance', 'risan']
b0376: cdai and ses-cd scores in the motivate, advance and fortify trials of risankizumab (anti-p19) in crohn s #acg2022 
I'm a Mayo specialist in evaluation and management of patients with ulcerative colitis and Crohn's disease. Tweets are mine. Retweet doesn't mean endorsement.